Ramona Ortez

Recommended Articles

• Lemtrada Gains FDA Approval to Treat Multiple Sclerosis

  In the United States alone, over 400,000 individuals are dealing with the challenges associated with multiple sclerosis (MS). Most recently, Sanofi, an international leader in healthcare, announced FDA approval of the prescription drug Lemtrada, for the treatment of patients with relapsing forms of...

• Navigating Through Clinical and Research Ethics

  When speaking of ethics in the medical field, it’s never so simple as the ethics that one learns at home or in other social settings. Ethics in this context have much more to do with a code of conduct, as well as a fair amount of patient advocacy. Depending on the arena of medicine and the...

• Why Alzheimer's Caregivers Are At Risk for Depression

  It’s a very common story. Someone receives a diagnosis of a disease or disorder that will at some point require constant care, then a loved one, a parent, spouse, child or sibling, jumps into caregiver mode. Over time, as the needs of the patient grows, the pressure of being a caregiver is 24/7...

• New Approach Found to Reverse Lymphoma Treatment Resistance

  Cancer tricks the immune system. The immune responses to cancerous cells are weak in cancer patients. The future is here to change that.Lymphoma is a blood cancer that presents when white blood cells begin behaving abnormally. They might divide faster and last longer, producing symptoms such as...

• Why Should We Eat Whole Grains?

  For centuries, whole grains (straight from the stalk of the plant) were an integral part of our diet until mills began to surface. Milling takes away the bran and germ from the grain, robbing it of its nutritious content. Although removing the bran and germ increases the shelf life of the product...

• FDA Approves Baricitinib for Adults with Active Rheumatoid Arthritis

  On June 1st of 2018, the US Food and Drug Administration (FDA) approved Olumiant (Baricitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more TNF inhibitor therapies. “We are pleased to provide RA...